NGFR regulates stromal cell activation in germinal centers.

Nerve growth factor receptor (NGFR) is expressed by follicular dendritic cells (FDCs). However, the role of NGFR in the humoral response is not well defined. Here, we study the effect of Ngfr loss on lymph node organization and function, demonstrating that Ngfr depletion leads to spontaneous germinal center (GC) formation and an expansion of the GC B cell compartment.

Demultiplexing Ig repertoires by parallel mRNA/DNA sequencing shows major differential alterations in severe COVID-19.

To understand the fine differential elements that can lead to or prevent acute respiratory distress syndrome (ARDS) in COVID-19 patients, it is crucial to investigate the immune response architecture. We herein dissected the multiple layers of B cell responses by flow cytometry and Ig repertoire analysis from acute phase to recovery. Flow cytometry with FlowSOM analysis showed major changes associated with COVID-19 inflammation such as an increase of double-negative B-cells and ongoing plasma cell differentiation.

[Perspectives for the evolution and use of CAR-T cells].

CAR-T cells have recently made a stunning entry on the arena of immunotherapy of B-cell lymphomas. This new treatment approach represents the culmination of 30 years of efforts to understand the role of T cells in the antitumor response. However, this technology is still in its infancy and suffers from a number of limitations.

Characterization of the novel HLA-DQA1*05:13 allele by next-generation sequencing.

DQA1*05:13 differs from DQA1*05:05:01:04 by one nucleotide substitution at position 37 in exon 1.

Characterization of the novel HLA-DQA1*05:18 allele by next-generation sequencing.

DQA1*05:18 differs from DQA1*05:01:01:03 by one nucleotide substitution at position 94 in exon 2.

Characterization of the novel HLA-DQA1*03:11 allele by next-generation sequencing.

DQA1*03:11 differs from DQA1*03:03:01:01 by one nucleotide substitution at position 664 in exon 4.

Characterization of the novel HLA-B*08:67:02N allele by next-generation sequencing.

HLA-B*08:67:02N differs from B*08:01:01:01 by one nucleotide substitution at position 224 in exon 2.

Characterization of the novel HLA-C*14:114 allele by next-generation sequencing.

HLA-C*14:114 differs from C*14:02:01:01 by one nucleotide substitution at position 1077 in exon 7.

High-Dimensional Phenotyping of Human Myeloid-Derived Suppressor Cells/Tumor-Associated Macrophages in Tissue by Mass Cytometry.

Myeloid-derived suppressor cells (MDSCs) and tumor-associated macrophages (TAMs) are heterogeneous cells that share myeloid markers and are not easily distinguishable in human tumors due to their lack of specific markers. These cells are a major player in the tumor microenvironment and are involved in the prognosis and physiopathology of various tumors. Here is presented a scheme to decipher these cells by mass cytometry.

Characterization of the novel HLA-DQA1*01:39 allele by next-generation sequencing.

DQA1*01:39 differs from DQA1*01:02:01:01 by one nucleotide substitution at position 49 in exon 1.

Characterization of the novel HLA-DQA1*01:38:01:01 allele by next-generation sequencing.

DQA1*01:38:01:01 differs from DQA1*01:02:01:01 by one nucleotide substitution at position 554 in exon 3.

Characterization of the novel HLA-A*24:470 allele by next-generation sequencing.

A*24:470 differs from A*24:02:01:01 by one nucleotide substitution at position 46 in exon 1.

Characterization of the novel HLA-DQA1*01:19 allele by next-generation sequencing.

DQA1*01:19 differs from DQA1*01:02:01:04 by one nucleotide substitution at position 731 in exon 4.

Characterization of the novel HLA-B*18:181 allele by next-generation sequencing.

B*18:181 differs from B*18:01:01:02 by one nucleotide substitution at position 1043 in exon 6.

Characterization of the novel HLA-B*15:474 allele by next-generation sequencing.

B*15:474 differs from B*15:01:01:01 by one nucleotide substitution at position 923 in exon 5.

Characterization of the novel HLA-B*40:450 allele by next-generation sequencing.

B*40:450 differs from B*40:01:02:01 by one nucleotide substitution at position 5 in exon 1.

Characterization of the novel HLA-B*51:296 allele by next-generation sequencing.

B*51:296 differs from B*51:01:01:01 by one nucleotide substitution at position 1030 in exon 6.

Characterization of the novel HLA-DQB1*02:162N allele by next-generation sequencing.

DQB1*02:162N differs from DQB1*02:02:01:01 by one nucleotide substitution at position 276 in exon 2.

Characterization of the novel HLA-DQB1*03:400N allele by next-generation sequencing.

DQB1*03:400N differs from DQB1*03:01:01:03 by one nucleotide insertion at position 535 in exon 3.

Characterization of the novel HLA-DRB1*01:107 allele by next-generation sequencing.

DRB1*01:107 differs from DRB1*01:01:01:01 by one nucleotide substitution at position 484 in exon 3.

Characterization of the novel HLA-DQB1*05:176 allele by next-generation sequencing.

DQB1*05:176 differs from DQB1*05:01:01:03 by one nucleotide substitution at position 184 in exon 2.

Characterization of the novel HLA-B*44:476 allele by next-generation sequencing.

B*44:476 differs from B*44:03:01:01 by one nucleotide substitution at position 934 in exon 5.